Comparative Pharmacology
Head-to-head clinical analysis: DIPROLENE AF versus LOCORTEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIPROLENE AF versus LOCORTEN.
DIPROLENE AF vs LOCORTEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Betamethasone dipropionate is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of phospholipase A2, thereby reducing the release of arachidonic acid and subsequent production of prostaglandins and leukotrienes. This results in anti-inflammatory, antipruritic, and vasoconstrictive effects.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Binds to glucocorticoid receptors, modulating gene expression to inhibit prostaglandin and leukotriene synthesis, reduce cytokine release, and suppress immune cell activation.
Apply a thin film to affected skin areas twice daily. Maximum 45 g per week. Not to exceed 2 consecutive weeks of treatment.
For mild to moderate dermatoses: Apply a thin film to affected area twice daily. For severe dermatoses: Apply a thin film to affected area three to four times daily. Topical use only. Not for ophthalmic use.
None Documented
None Documented
Approximately 2.5-3 hours (terminal half-life) for betamethasone dipropionate (active moiety); clinical effects persist beyond half-life due to receptor-mediated activity.
100 hours (terminal). Clinical context: prolonged in hepatic impairment; single daily dosing sufficient for psoriasis.
Primarily hepatic metabolism; inactive metabolites excreted renally (approximately 80-85% as metabolites in urine) and fecally (approximately 15-20%).
Renal: ~75% (inactive metabolites); biliary/fecal: ~25%. <1% unchanged.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid